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1 who described 39 patients with urinary tract infection (UTI) caused by Enterobacteriaceae with extended-spectrum b-lactamases (ESBLs) who were treated with pivmecillinam. The authors reported the bacteriological cure rate to be 79% with a clinical cure reported in 16 of 19 evaluable patients (84%). A number of studies have reported in vitro susceptibility of ESBL-producing Enterobacteriaceae to mecillinam despite the fact that mecillinam is labile to most b-lactamases (including TEM-1) and that MICs are elevated when high inocula are used. 2 This has led some to advocate the use of mecillinam with or without clavulanate for treatment of uncomplicated UTIs only. 1, 3 It is frequently stated that NDM-1 (and other metallocarbapenemases) confers resistance to all b-lactam antibiotics except aztreonam. 4 However, in one study in Pakistan it was noted that Enterobacteriaceae with NDM-1 were typically susceptible to mecillinam (MIC ≤8 mg/L). 5 We determined the MICs of mecillinam for a large collection of Enterobacteriaceae with NDM-1 carbapenemase (n ¼ 87) obtained from three separate screening studies in Pakistan. These isolates were all cultured from stool samples from different patients. We also tested other Enterobacteriaceae with other carbapenemases, including IMP (n¼ 9), VIM (n¼ 7), KPC (n¼ 11) and OXA-48 (n¼ 14). All were clinical isolates obtained from diverse international sources. The MICs of mecillinam (range 0.06-32 mg/L) were determined using multipoint inoculation of 10 4 cfu/spot on Iso-Sensitest agar 6 and also using a high inoculum of 10 6 cfu/spot as previously described. 2 All MICs of mecillinam were also determined (at both inocula) in the presence of a fixed concentration of 2 mg/L potassium clavulanate. All tests were performed in duplicate on separate occasions. Rates of susceptibility were compared using Fisher's exact test with P,0.05 as an indicator of statistical significance. Table 1 shows the MICs of mecillinam for 87 isolates of Enterobacteriaceae with NDM-1. Of these 87 isolates, 18.4% also produced AmpC enzyme, 29.9% had ESBL and 41.4% had both ESBL and AmpC. The collection included Escherichia coli (n ¼ 29), Klebsiella pneumoniae (n ¼ 24), Enterobacter cloacae (n ¼ 22) and four other species (n ¼ 12). The results show that, when using a standard MIC test, 83.9% of isolates were susceptible to mecillinam (MIC ≤8 mg/L). Rates of susceptibility for NDM-1-producing E. coli and E. cloacae were very high (96.5% -100%), with only one resistant E. coli isolate encountered, whereas the susceptibility rate of K. pneumoniae was much lower (50%; P, 0.0001). When using a high inoculum (10 6 cfu), only six isolates of Enterobacteriaceae (6.9%) remained susceptible (P,0.0001) and none of these harboured an ESBL. The inclusion of clavulanate (2 mg/L) had some impact on the restoration of susceptibility when high inocula were used (27.6% of isolates susceptible with clavulanate added versus 6.9% without; P ¼ 0.0005).
MICs of mecillinam for isolates with KPC (n ¼ 11) and VIM (n¼ 7) carbapenemases were.32 mg/L under all test conditions (data not shown) and only 3/14 isolates with OXA-48 were susceptible to mecillinam. However, 8/9 isolates with IMP carbapenemase were susceptible to mecillinam with MICs of 2 -4 mg/L (Table 1) .
Despite the encouraging results reported by Janså ker et al.,
1
reports on the efficacy of mecillinam for the treatment of ESBLproducing Enterobacteriaceae show mixed success. Titelman et al. 7 reported the treatment of eight patients with pivmecillinam who all had UTI and showed a good clinical response. Although bacteriological cure rates were low (2/8), none of the patients with persisting bacteriuria had a relapse of UTI symptoms within 6 months. Søraas et al. 8 recently published an observational population-based study of patients in Norway who were treated for community-acquired UTI. They observed mecillinam treatment failure in 44% of patients infected with ESBL-producing strains compared with only 14% of patients infected with non-ESBL-producing strains. Most of the patients received a dose of 200 mg three times daily in accordance with national guidelines. This was in contrast to the study by Janså ker et al., 1 in which 77% of patients received twice this dose (400 mg three times daily), and this is likely to be a factor in the difference in outcomes between these studies.
Our study suggests that mecillinam is a relatively poor substrate for hydrolysis by NDM-1 carbapenemase and most of the isolates (83.9%) possessing this enzyme were susceptible under standard test conditions. The proportion of resistant isolates was much higher for K. pneumoniae (50%) than for E. coli (3.5%). Although there was a substantial increase in mecillinam resistance when the inoculum was increased 100-fold, this is likely to be the case for other antibiotics to which these bacteria are, on occasion, deemed to be susceptible-not least carbapenems. 5 Enterobacteriaceae with NDM-1 are common in both hospitals and the community in areas of the Indian subcontinent 5 and are isolated with increasing frequency in countries across the world. 9 Such isolates frequently have resistance to a wide range of antimicrobials and treatment options may become increasingly limited. In such circumstances, the use of mecillinam alone, or in combination with other agents, may warrant further investigation into its potential in the treatment of uncomplicated UTI.
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Sir, We report the case of a middle-aged woman with a history of insulin-dependent diabetes mellitus, chronic kidney disease and bilateral nephrolithiasis admitted to our hospital for weakness, falls and a 2 day history of diffuse abdominal pain. Admission vital signs showed a temperature of 96.48F, a pulse of 94 bpm and blood pressure of 142/80 mmHg. Her examination showed a non-toxic appearing female with a diffusely tender abdomen. She had no rebound, guarding or flank tenderness. CT imaging of the abdomen revealed a small right-sided non-obstructing renal calculus, a previously placed right double-J ureteral stent and a large left staghorn calculus.
Admission laboratory data included a white blood cell count of 26.3×10 9 /L (89% neutrophils), haemoglobin 9.6 g/dL, platelets 352×10 9 /L, blood urea nitrogen 69 mg/dL and creatinine 5.9 mg/dL (baseline creatinine 1.7 mg/dL). Using the Cockcroft and Gault method, the estimated creatinine clearance was 20 mL/min. 1 Urinalysis showed pyuria with .50 white blood cells and many bacteria. The patient was empirically treated with vancomycin and piperacillin/tazobactam. Her urine culture grew .100000 cfu/mL of Klebsiella pneumoniae. Two sets of blood cultures drawn at the time of admission also grew K. pneumoniae. All isolates were a carbapenem-resistant K. pneumoniae susceptible to amikacin, colistin and tigecycline only. No molecular typing was performed. Susceptibility testing was performed initially using a Microscan Gram Negative Combo Panel 41 (Siemens Healthcare Diagnostics Inc., West Sacramento, CA, USA). Carbapenemase production was confirmed by the modified Hodge test performed in accordance with CLSI document M100-S20. 2 For both blood and
